Gland Pharma Ltd

An independent audit verified a company’s Business Responsibility and Sustainability Report (BRSR), revealing key environmental, social, and governance (ESG) performance indicators. The report, assessed across multiple sites including Hyderabad, Dundigal, Pashamylaram, and JNPC, indicated a total waste generation of 3,223.79 metric tons, with a substantial 2,087.62 MT classified as “Other Hazardous Waste,” prompting a need for further review. While the company reports zero work-related injuries and fatalities, only 8.36% of total wages are paid to female employees, highlighting a potential area for improvement in gender diversity. The report also noted that all two Prevention of Sexual Harassment (POSH) complaints filed were upheld, suggesting a need to strengthen preventative measures. Purchases are heavily concentrated among a few trading houses and dealers, representing a potential supply chain risk.

Gland Pharma Limited announced that its ESOP Compensation Committee has allotted 6,979 equity shares of Re. 1/- each to 8 employees on the exercise of stock options under the Gland Pharma Employee Stock Options Scheme, 2025. Consequently, the company's issued, subscribed, and paid-up share capital increased to Rs 164,966,661, comprising 164,966,661 equity shares of Re. 1/- each.

Three employees were granted 16,790 options under the ESOP 2025 scheme on July 30, 2026, as announced by the company’s Board of Directors. The options, administered by the ESOP Compensation Committee, comply with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. A portion of the options, 11,081, were granted at an exercise price of INR 1258.50, which represents 50% of the NSE closing price on the grant date, while 5,709 options were granted at the face value of INR 1 per share. The vesting schedule is tiered, with 34% vesting after one year, 33% after two years, and the remaining 33% after three years, with a two-year exercise period following each vesting date. To date, no shares have been issued or realized from the exercise of these options, and there have been no variations or cancellations to the scheme.

Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, which is bioequivalent and therapeutically equivalent to Merck Sharp the product had US sales of approximately USD 1.6 billion for the twelve months ending April 2026, according to IQVIA.

Gland Pharma (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION' Injection of Merck Sharp & Dohme LLC. The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

The approval covers 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. The approved product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's BRIDION Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. The company said it has commercially launched the product in the U.S. on the first day of approval through its marketing partner. According to IQVIA, Sugammadex Injection recorded U.S. sales of about $1.6 billion during the 12 months ended April 2026, highlighting a sizeable market opportunity. Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics. It operates in more than 60 countries under a business-to-business model and offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions. On a consolidated basis, Gland Pharma's net profit surged 96.57% to Rs 366.68 crore while net sales rose 22.31% to Rs 1742.79 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 10 August 2026.

Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2510.4, up 1.92% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Gland Pharma Ltd has gained around 11.68% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 6.18 lakh shares today, compared to the daily average of 8.44 lakh shares in last one month.The PE of the stock is 30.83 based on TTM earnings ending March 26.Powered by Capital Market - Live

Gland Pharma announced that Satyanarayana Murthy Chavali, DIN: 00142138, Independent Director of the Company has tendered resignation to his directorship in the Company with effect from 15 June 2026.

Great Eastern Shipping Company Ltd, Premier Energies Ltd, ICICI Prudential Life Insurance Company Ltd, Amber Enterprises India Ltd are among the other stocks to see a surge in volumes on NSE today, 18 May 2026.Gland Pharma Ltd notched up volume of 52.97 lakh shares by 14:14 IST on NSE, a 27.13 fold spurt over two-week average daily volume of 1.95 lakh shares. The stock rose 14.05% to Rs.2,130.80. Volumes stood at 1.42 lakh shares in the last session.Great Eastern Shipping Company Ltd clocked volume of 152.92 lakh shares by 14:14 IST on NSE, a 9.69 times surge over two-week average daily volume of 15.78 lakh shares. The stock gained 10.07% to Rs.1,688.30. Volumes stood at 97.54 lakh shares in the last session.Premier Energies Ltd registered volume of 48.25 lakh shares by 14:14 IST on NSE, a 5.44 fold spurt over two-week average daily volume of 8.87 lakh shares. The stock rose 1.56% to Rs.996.90. Volumes stood at 7.51 lakh shares in the last session.ICICI Prudential Life Insurance Company Ltd notched up volume of 56.33 lakh shares by 14:14 IST on NSE, a 5.24 fold spurt over two-week average daily volume of 10.75 lakh shares. The stock slipped 3.02% to Rs.519.45. Volumes stood at 4.82 lakh shares in the last session.Amber Enterprises India Ltd saw volume of 18.39 lakh shares by 14:14 IST on NSE, a 5.13 fold spurt over two-week average daily volume of 3.59 lakh shares. The stock dropped 14.67% to Rs.7,233.00. Volumes stood at 3.79 lakh shares in the last session.Powered by Capital Market - Live